Somaxon Pharmaceuticals Announces Presentation Of Phase 2 SILENOR(TM) Data At The Associated Professional Sleep Societies Annual Meeting

... Somaxon Pharmaceuticals,Inc. (Nasdaq: SOMX) today announced that data from its Phase 2 clinicaltrial evaluating three doses of SILENOR(TM) (doxepin HCL) in elderly adultswith insomnia will be presented at the SLEEP 2006 Annual Meeting of theAssociated Professional Sleep Societies. The data will be presented byThomas Roth, Ph.D. [click link for full article] ...